Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan M Domchek

Showing results (81-90 of 361) with videos related to

Pageof 37
Sort By:
Clinical Breast Cancer|March 27, 2012
Quality of life in long-term survivors of metastatic breast cancerJane L Meisel, Susan M Domchek, Robert H Vonderheide, et al.
Gynecologic Oncology|May 11, 2021
What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomyMartha Hickey, Katrina M Moss, Gita D Mishra, et al.
Cancer|June 5, 2003
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaJohanna C Bendell, Susan M Domchek, Harold J Burstein, et al.
Cancer|July 18, 2013
Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based studyAnne Marie McCarthy, Mirar Bristol, Tracey Fredricks, et al.
AJR. American Journal of Roentgenology|May 6, 2026
Risk Stratification for Breast Cancer Screening: <i>AJR</i> Expert Panel Narrative ReviewCody Schopf, Susan M Domchek, Jeffrey A Tice, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2026
Longitudinal Association of Quantitative Background Parenchymal Enhancement with Breast Cancer Risk Among Women with BRCA1/2 Pathogenic VariantsAlex A Nguyen, Eric A Cohen, Sarah Ehsan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 21, 2024
Multi-ethnic heterozygote frequencies of cancer susceptibility genes to inform counseling of reproductive riskJacquelyn Powers, Heather Wachtel, Erica Trujillo, et al.
Familial Cancer|June 1, 2010
Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous studyNoralane M Lindor, Kiley J Johnson, Hayden Harvey, et al.
Breast Cancer Research and Treatment|March 12, 2013
Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American womenAnne Marie McCarthy, Katrina Armstrong, Elizabeth Handorf, et al.
Genetic Testing|April 1, 2008
Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutationsEsme Finlay, Jill E Stopfer, Eric Burlingame, et al.
Pageof 37

Showing results (81-90 of 361) with videos related to

Sort By:
Pageof 37
Clinical Breast Cancer|March 27, 2012
Quality of life in long-term survivors of metastatic breast cancerJane L Meisel, Susan M Domchek, Robert H Vonderheide, et al.
Gynecologic Oncology|May 11, 2021
What Happens After Menopause? (WHAM): A prospective controlled study of cardiovascular and metabolic risk 12 months after premenopausal risk-reducing bilateral salpingo-oophorectomyMartha Hickey, Katrina M Moss, Gita D Mishra, et al.
Cancer|June 5, 2003
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinomaJohanna C Bendell, Susan M Domchek, Harold J Burstein, et al.
Cancer|July 18, 2013
Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based studyAnne Marie McCarthy, Mirar Bristol, Tracey Fredricks, et al.
AJR. American Journal of Roentgenology|May 6, 2026
Risk Stratification for Breast Cancer Screening: <i>AJR</i> Expert Panel Narrative ReviewCody Schopf, Susan M Domchek, Jeffrey A Tice, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|June 10, 2026
Longitudinal Association of Quantitative Background Parenchymal Enhancement with Breast Cancer Risk Among Women with BRCA1/2 Pathogenic VariantsAlex A Nguyen, Eric A Cohen, Sarah Ehsan, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|November 21, 2024
Multi-ethnic heterozygote frequencies of cancer susceptibility genes to inform counseling of reproductive riskJacquelyn Powers, Heather Wachtel, Erica Trujillo, et al.
Familial Cancer|June 1, 2010
Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous studyNoralane M Lindor, Kiley J Johnson, Hayden Harvey, et al.
Breast Cancer Research and Treatment|March 12, 2013
Incremental impact of breast cancer SNP panel on risk classification in a screening population of white and African American womenAnne Marie McCarthy, Katrina Armstrong, Elizabeth Handorf, et al.
Genetic Testing|April 1, 2008
Factors determining dissemination of results and uptake of genetic testing in families with known BRCA1/2 mutationsEsme Finlay, Jill E Stopfer, Eric Burlingame, et al.
Pageof 37